Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
NEJM study shows strong protection across strains
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The event will bring together industrial leaders, technology providers, and policymakers to discuss real-world Industrial AI applications in Bangalore
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Subscribe To Our Newsletter & Stay Updated
